Hong Kong International Wine & Spirits Fair opens next month ACN Newswire

Hong Kong International Wine & Spirits Fair opens next month

- Over 600 exhibitors from 20 countries and regions, Mainland China participation up by 60% year-on-year- Showcasing the world’s finest wines and spirits, including Chinese wines and baijiu, Japanese sake and shochu, vodka, brandy, and more- Inaugural Sommelier's Picks will engage renowned sommeliers to feature their favourite wine lists to industry professionals and the publicHONG KONG, Oct 21, 2024 - (ACN Newswire via SeaPRwire.com) - The 16th HKTDC Hong Kong International Wine & Spirits Fair will be held on 7-9 November at the Hong Kong Convention and Exhibition Centre (HKCEC), showcasing fine wines and spirits from around the world, along with related products and services to trade visitors and buyers.With Hong Kong reducing the liquor duty rate, as announced during the Policy Address last week, to promote liquor trade and boost the development of high value-added industries, the Wine & Spirits Fair will enable the industry to seize opportunities presented by this measure.Sophia Chong, Deputy Executive Director of the Hong Kong Trade Development Council (HKTDC), said: "To cater to consumers’ more sophisticated and diverse appreciation for wines, this year's Wine & Spirits Fair offers a diverse range of wines and spirits from around the world to enhance the tasting experience and promote knowledge of wine through a series of special events. The market for Chinese baijiu and wine is thriving, especially following the recent proposal by the Hong Kong SAR Government to reduce taxes for high-end liquor. This year's Fair brings together more than 600 exhibitors, with a notable increase in those showcasing Chinese baijiu and spirits around the world. Overall, participation from Mainland China has increased by 60% by scale compared to the previous year. The HKTDC is actively recruiting more buyers to take part in the Fair, further promoting Hong Kong as a regional trading hub for wine and spirits."This year's Fair will bring together more than 600 exhibitors from 20 countries and regions. In addition to exhibitors from Hong Kong and the Mainland China, there are overseas exhibitors from all over the world, including those from Belarus, the Czech Republic, Denmark, France, Germany, Ireland, Italy, Poland, and the United Kingdom from Europe.Exhibitors from the Americas included Argentina, Canada, Chile, Mexico and the United States. Australia, Japan and the Philippines make up the Asia-Pacific representation, while South Africa will participate for the first time.A global showcase for exquisite wines and spiritsThe Wine & Spirits Fair will feature a diverse range of alcoholic beverages, including old-world and new-world wines, Chinese wines, Japanese sake as well as spirits from around the world, including Chinese baijiu, Japan’s shochu, vodka and brandy. A variety of whiskies will also be showcased in both the Ireland and Japan pavilions.Exhibited beverages include:- Azienda Agricola Sciara 760 Metri Etna Rosso, making its fair debut, crafted by Stef Yim, Hong Kong’s first winemaker to set up a winery and vineyards at Mount Etna in Sicily, Italy. The nutrients from the volcanic mud and the high-altitude environment give this red wine its special aroma and flavour;- Zhenjiu, Chinese Baijiu from Guizhou in Mainland China, a high-end sauce aroma aijiu. Its rich and full body with a complex layering of spice and fermented bean flavors leaves a long-lasting aftertaste;- Fenjiu from Shanxi, traditional Chinese liquor crafted mainly from sorghum, which epitomises the light aroma style of baijiu with its crystal-clear appearance and a delightful aroma;- Clonakilty Single Pot Still Irish Whiskey, winner of two global awards, triple-distilled and matured on the Atlantic coastline in Clonakilty, Ireland. It presents flavours of sweet vanilla, toffee apple, salted caramel and wood spices, with a dark chocolate and orange finish;- Wabi Sabi Gin, developed by Japan’s pioneering female spirits entrepreneur Wakae. This gin features 13 botanicals, including Japanese citrus herbs and roses from Shimane Prefecture, creating layered flavours and a long finish;- Ukishiro Sakitama Kodaishu 20 years aged by Yokota Sake Brewery, which has won 22 gold medals in the Annual Japan Sake Awards;- Vinette Premium Canned Wines, a distinguished South African brand and gold medalist in the Gilbert & Gaillard International Challenge, renowned for crafting premium table wines in innovative aluminium cans.The Wine & Spirits Fair also features the Friends of Wine zone, which showcases a variety of gourmet foods designed to complement the wines. Some exhibitors, such as Asia Wine Service & Education Centre (AWSEC), will also introduce their services that promote the industry’s all-round development.Multiple events explore market trendsConferences, tasting sessions and seminars hosted by world-class Masters of Wine, sommeliers and industry professionals, will analyse trends in various markets, while offering attendees an opportunity to sample fine wines from around the world.The inaugural Sommelier's Picks will engage three renowned sommeliers, Arnaud Bardary MS, Carlito Chiu and Reeze Choi, second runner-up of ASI Best Sommelier of the World Contest 2023 who will share their favourite wine lists with both industry professionals and the public.A wine industry conference will be hosted by Master of Wine Debra Meiburg, which will explore consumption trends and preferences of alcoholic beverages among Generation Z and millennials. Jennifer Docherty, the first ethnically Chinese and Mandarin-speaking Master of Wine, will share her expertise on blind-tasting fine wines, while renowned wine critic and chief editor Lau Chi Sun will explore hot topics, such as the outlook for Hong Kong’s spirits market and impact of Hong Kong’s taxation system, in a seminar organised by Wine Now.Prize presentation ceremonies and competitions at the Fair include:- Cathay Hong Kong International Wine and Spirit Competition 2024;- Washu Awards 2024;- Hong Kong Best Spirits Awards 2024;- WineLuxe’s Hong Kong Top 10 Wine Pairing Restaurant Awards Presentation Ceremony 2024- Hong Kong International Mixology Showdown 2024 - Hong Kong region semi-final and the final of the debut Greater Bay Area region contest.Public Day welcomes wine loversOn the final day, the Wine Fiesta Zone will be open to public ticket holders to sample and buy a range of wines and spirits, while enjoying wine tasting experiences through a variety of activities.Both buyers and ticket-holding members of the public aged 18 or above are welcome. Regular tickets are priced at HK$200, with specially-priced tickets at HK$99 available from 23 October via BOOKYAY, CTG, HK01, HKTVMall, HKGO, KKDay, KLOOK, PopTicket, Timable, Trip.com, Lan Kwai Fong Group, Winenow, Wai Shing Wine International CO., Ltd. and Zicket.Special ticket buyers will receive a Lucaris crystal wine glass and discounts on Hong Kong Airlines tickets on a first-come, first-served basis.Among other highlights, the Public Day will feature a seminar on sparkling wines hosted by Master of Wine Debra Meiburg.Stef Yim, Hong Kong-born “Volcano Winemaker”, will take to the stage sharing his unique brewing journey.The public will also hear from three experts on the career path of sommeliers.Representatives from Lan Kwai Fong (LKF) have crafted a special cocktail “HK & Suit” for the Fair, featuring passion fruit and Japanese Akori Gin, among other ingredients. This cocktail will be available for purchase in the HKTDC x LKF Cocktail Festival inside the Wine Fiesta Zone.Relevant data:Spirits Trade in value terms2023Jan - Aug 2024Trade in value termsHK$BGrowth %HK$BGrowth %Total Exports49.29+48.436.62+16.24Imports61.02+54.639.86+2.7HKTDC Research Analysis and News - Duty Cut Set to Boost Hong Kong’s Regional Spirits Hub Prospects:https://research.hktdc.com/en/article/MTgyODQ3ODEwMgPhoto download: https://bit.ly/4heUSUpAt the press conference, HKTDC Deputy Executive Director Sophia Chong (centre) announced that the 16th International Wine & Spirits Fair will bring together more than 600 exhibitors from 20 countries and regions. The HKTDC is actively recruiting more exhibitors and buyers to take part, further promoting Hong Kong as a regional trading hub for wine and spirits. Jennifer Docherty, Master of Wine (left), and Reeze Choi, second runner-up of ASI Best Sommelier of the World Competition 2023 (right), also analysed industry trends at the press conferenceSophia Chong, HKTDC Deputy Executive Director (front row, fifth right), Jennifer Docherty, Master of Wine (front row, fifth left), sommelier Reeze Choi (front row, fourth right) and representatives from consulates and industry organisations attended the 16th HKTDC Hong Kong International Wine & Spirits Fair press conferenceThis year's Fair will bring together more than 600 exhibitors from 20 countries and regions, including Hong Kong and Mainland China, as well as overseas exhibitors from around the world, including Europe, the United States and the Asia-Pacific region (Photo: Jon Dory Limited promoting whisky from Scotland)The Wine & Spirits Fair will showcase fine wines and spirits from around the world as well as related products and services to trade visitors and buyers, promoting Hong Kong as a regional trading hub for wine and spiritsSake Z, an exhibitor at the Wine & Spirits Fair, brought a kiosk with a wide selection of sakes for participants to tryFenjiu from Shanxi, a traditional Chinese liquor crafted mainly from sorghum, which epitomises the light aroma style of baijiu with its crystal-clear appearance and delightful aromaUkishiro Sakitama Kodaishu 20 years aged by Yokota Sake Brewery has won 22 gold medals in the Annual Japan Sake AwardRepresentatives from Lan Kwai Fong (LKF) crafted a special cocktail for the Wine & Spirits Fair, called HK & Suit, with notes of passion fruit and Japanese Akori Gin, among other ingredientsWebsiteHong Kong International Wine & Spirits Fair: https://www.hktdc.com/event/hkwinefair/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Kelly ShekTel: (852) 2584 4537Email: kelly.yt.shek@hktdc.orgSnowy ChanTel: (852) 2584 4525Email: snowy.sn.chan@hktdc.orgAbout HKTDC The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via trade publications, research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2024 ACN Newswire via SeaPRwire.com.
More

康哲藥業入選2024年度「中國醫藥上市公司ESG競爭力」系列榜單

深圳, 2024年10月21日 - (亞太商訊 via SeaPRwire.com) -近日,E藥經理人聯合中國領先的企業社會責任獨立諮詢機構發佈2024年度「中國醫藥上市公司ESG競爭力」系列榜單,旨在表彰在ESG管理各方面具有標杆作用的中國醫藥企業。康哲藥業憑藉在可持續發展、低碳行動方面的不斷努力,連續三年入選「中國醫藥上市公司ESG競爭力TOP20(中盤股)」榜單,並入選首屆「中國醫藥上市公司低碳先鋒TOP10」榜單。康哲藥業作為可持續發展理念的積極踐行者,切實響應聯合國可持續發展目標,將ESG治理與集團宏觀戰略和業務運營深度融合。集團堅持高商業道德標準的運營,已構建科學有效的風險識別與管控體系,並堅持高質量創新,為各利益相關方提供專業、優質的產品和服務。同時,康哲藥業切實關心員工及周邊社區的發展,踐行暖心捐贈、扶貧濟困、關懷弱勢群體等活動。康哲藥業亦不斷探索對生態環境影響更小的運營發展模式,從「企業治理、策略、風險管理、目標規劃」等維度著手,積極推進氣候風險評估、分析與應對工作,為減緩全球氣候變化貢獻力量。康哲藥業持續推動ESG管理實踐的進步,獲得了全球權威ESG專業評級機構的廣泛認可,其ESG表現位於全球同業前列。康哲藥業明晟MSCI ESG評級維持「AA」;標普全球(S&P Global)ESG評分超過全球95%的參評同業,並連續兩年獲入選標普全球《可持續發展年鑑(中國版)》;香港品質保證局(HKQAA)可持續發展評級位於行業前10%水平;華證指數ESG評級為「AA」。未來,康哲藥業將繼續堅持負責任、可持續運營,推動企業與醫藥行業綠色轉型,以實際行動支持人類邁入可持續的繁榮發展之路。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More
國泰君安國際榮獲HKQAA香港綠色和可持續金融大奬 2024多項殊榮 ACN Newswire

國泰君安國際榮獲HKQAA香港綠色和可持續金融大奬 2024多項殊榮

香港, 2024年10月21日 - (亞太商訊 via SeaPRwire.com) - 國泰君安國際控股有限公司(「國泰君安國際」、「公司」或「集團」,股份代號:1788.HK)宣佈,公司憑藉在綠色金融服務及可持續發展領域之卓越表现,於香港品質保證局(Hong Kong Quality Assurance Agency,簡稱HKQAA)舉辦的「香港綠色和可持續金融大奬 2024」中,榮獲多項殊榮﹐包括:「傑出綠色和可持續貸款發行機構(證券金融服務業)- 卓越遠見可持續發展掛鉤貸款績效指標」大獎,公司董事會主席、執行董事閻峰博士榮獲「傑出綠色和可持續金融發展領袖」獎項,及公司董事會辦公室聯席董事余欣女士獲得「傑出綠色和可持續金融發展策略專才」獎項。國泰君安國際始終堅持踐行金融服務實體經濟的理念,積極支持和推動企業客户的綠色轉型。2023年,公司參與完成的可持續金融業務發行總量超過800億港元。同時,公司不斷進行可持續發展的多元化探索,今年年初,公司與華僑銀行(香港)簽訂了中國內地及香港地區證券行業首筆可持續發展挂鈎貸款,爲業界ESG發展樹立了典範。此次獲獎,標誌著行業權威機構對國泰君安國際致力於促進自身及社會整體可持續發展實踐的高度肯定。未來,公司將進一步提升在綠色及可持續金融領域的參與度及競爭力,為行業及社會可持續發展作出積極貢獻。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More
Majority of Singapore Employees Comfortable Discussing Mental Health at Work, foundit Survey Reveals ACN Newswire

Majority of Singapore Employees Comfortable Discussing Mental Health at Work, foundit Survey Reveals

Positive strides in work-life balance and mental health openness highlight progress,while workload challenges present opportunities for improvementKey findings from the survey:57% of employees report a positive work-life balance, with 37% calling it "Good" and 20% calling it "Excellent."35% are actively using wellness programs, reflecting growing engagement in well-being initiatives.46% rarely or never experience burnout, though 37% occasionally face it, highlighting areas for support.66% report heavy workloads, pointing to the need for better workload management.SINGAPORE, Oct 21, 2024 - (ACN Newswire via SeaPRwire.com) - A recent survey by foundit, a leading jobs and talent platform, highlights encouraging developments in Singapore's workplaces. The study reveals that 57% of employees rate their work-life balance as "Good" or "Excellent," and 51% feel comfortable discussing mental health issues with their managers or HR.These findings reflect a growing emphasis on employee well-being and a more open dialogue around mental health in the corporate environment.However, despite these positive trends, the survey also uncovers areas that warrant attention. A significant 66% of employees report heavy workloads, suggesting room for improvement in workload distribution and management.Additionally, while 35% of respondents are engaging with wellness programs, a notable portion of employees have not yet utilised these resources, which may impact their ability to manage stress effectively.As a result, 37% of employees occasionally experience symptoms of burnout, such as exhaustion or reduced professional efficacy. This underscores the need for continued support and resources to help employees cope with workplace demands.Sekhar Garisa, CEO of foundit, commented on the survey:"It's heartening to see that a significant number of employees in Singapore are enjoying a positive work-life balance and feel comfortable discussing mental health at work. This marks a substantial step forward in creating supportive workplace cultures. While there are areas that warrant attention, such as workload management and addressing burnout, the overall findings are encouraging. By continuing to focus on employee well-being, Singaporean businesses can enhance productivity, foster innovation, and maintain their position as leaders in the global economy."Key Survey Highlights: Building on Positive MomentumThe survey underscores the progress made in Singapore's corporate sector and identifies opportunities for further enhancement:Work-Life Balance: 57% of employees report a positive work-life balance—37% rating it as "Good" and 20% as "Excellent". By supporting the 43% who rated their balance as "Fair" (27%) or "Poor" to "Very poor" (16%), organisations can further promote harmony between professional and personal lives.Increasing Mental Health Openness: A significant 51% of employees feel comfortable discussing mental health issues with their manager or HR, comprising 23% who are "Very comfortable" and 28% who are "Comfortable."Wellness Program Engagement: While 35% of respondents have utilised employee wellness programs, there's an opportunity to reach the 38% who haven't yet participated and the 27% who are unaware of such initiatives.Workload Management: 66% of employees report heavy workloads (42% "Heavy" and 24% "Extremely heavy"), giving organisations a chance to improve workload distribution.Addressing Burnout: Encouragingly, 46% of employees rarely or never experience burnout symptoms (24% "Never," 22% "Rarely"). Organisations need to support the 37% who occasionally face challenges.Key Stress Factors: Employees identify workload (37%), and lack of support (34%) as the top contributors to work-related stress. Addressing these areas offers organisations a clear focus for enhancing employee satisfaction and reducing stress.Looking AheadSingapore's workplaces have made notable strides in fostering environments that support employee well-being. By addressing areas that need attention and building upon the positive trends identified, organisations can create even more supportive and productive workplaces.As Singapore continues to evolve as a global business leader, emphasising employee well-being will contribute to sustained economic growth and social development. The findings from foundit's survey not only celebrate progress but also serve as a roadmap for continued improvement.By providing valuable insights into current workplace dynamics, the survey equips organisations with the information needed to implement effective strategies that enhance employee well-being and productivity.About foundit - APAC & Middle Eastfoundit, formerly Monster (APAC & ME) is Asia’s leading jobs and talent platform offering comprehensive employment solutions to recruiters and job seekers across APAC & ME. In addition to a powerful AI-powered job search, foundit offers e-learning, assessments, and services related to resume creation, interview preparation, and professional networking. Since its inception, the company has assisted over 120 million job seekers across 18 countries in upskilling and connecting them with the right job opportunities. foundit is now also the Official Talent Partner of the Badminton World Federation across 20 key world tour events. Over the last two decades, the company has been a leader in the world of recruitment solutions and has recently launched a cutting-edge solution to give recruiters access to passive candidates in addition to active ones. With the use of advanced technology, foundit is seeking to efficiently bridge the talent gap across industry verticals, experience levels, and geographies.Today, foundit is committed to enabling and connecting the right talent with the right opportunities by harnessing the power of deep tech to sharpen hyper-personalised job searches and offer precision hiring.To learn more about, foundit in APAC & Gulf, visit:Singapore: https://www.foundit.sgPhilippines: https://www.foundit.com.phMalaysia: https://www.foundit.myIndia: https://www.foundit.inGulf: https://www.founditgulf.comHong Kong: https://www.foundit.hkIndonesia: https://www.foundit.idContact:For media inquiries or further information, please contactNamrata Sharma – Namrata.sharma@adfactorspr.comContact number - +65 81383034 Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Learn & Get Inspired at the Global STEM Confex ACN Newswire

Learn & Get Inspired at the Global STEM Confex

DUBAI, UAE, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - The Global STEM Education Confex is back for its 11th edition, hosted by IBEForuM, happening on 6-7 November 2024 promises to be an unparalleled platform for knowledge exchange, collaboration, and innovation among educators, researchers, policymakers, and industry leaders. Set against the backdrop of the stunning Millennium Plaza Downtown Hotel in Dubai, this premier event is designed to connect thought leaders and drive the future of STEM education.This year’s Confex will gather top-notch speakers from around the globe, including 29 distinguished speakers and representatives from education ministries. With over 500+ delegates expected to attend from various countries, the conference is set to be a vibrant hub of ideas and solutions. The event is supported by 26 media partners and 22 sponsors, from across the globe with more to be announcedEvent Highlights:Engage with Policymakers and Industry Leaders: Collaborate to align STEM education with industry needs, ensuring a workforce equipped for future challenges.Hands-on Workshops and Interactive Labs: Participate in immersive sessions that provide practical insights and applicable skills in STEM education.Global Collaboration Opportunities: Network with educators, researchers, and innovators from around the world to discover potential partnerships.Explore Cutting-edge Advancements: Stay informed about the latest technologies and educational tools transforming STEM learning.Join us for this prestigious event, where STEM education and innovation meet to create lasting global impact. We look forward to welcoming you to Dubai!Event Details:Date: 6-7 NovemberVenue: Millennium Plaza Downtown Hotel, Dubai, UAEAbout IBEForuMIBEForuM is an International Organization with the goal of empowering global leaders to carve a better future. We are here to solve our shared global challenges through the power of collaboration. We help your business to build a sustainable future by synergizing ideas and infusing innovative solutions. Our insights and quality services help build trust and confidence giving birth to a ground-breaking alliance between academic research and practitioners thus helping them excel in this era of the digital revolution.Our extensive cross-industry connections bring together high calibre, industry leaders to provide the latest policy updates, strategic insight, and practical guidance. We deliver a broad range of industry-specific services that help create valuable relationships between our clients, their customers, employees, and regulatory authorities. We drive transformation by leveraging our cross-functional expertise across various domains. For more information, visit www.ibeforum.com.Speaking and Sponsorship Opportunities:For those interested in contributing to this significant event:Speaking Opportunities:Contact Arif Ulla+91 9845-113-293Email - arif.ulla@ibeforum.com Sponsorship Opportunities: Reach out to Imroze Shaik +91 9901-955-118Email - imroze.shaik@ibeforum.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More

雲頂新耀宣佈中國台灣地區藥政部門批准全球首個對因治療IgA腎病藥物耐賦康®的新藥上市許可申請

上海, 2024年10月21日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀(HKEX 1952.HK)是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司,今日宣佈,中國台灣地區藥政部門(TFDA)已批准耐賦康®(布地奈德腸溶膠囊,NEFECON®)用於治療罹患原發性免疫球蛋白A腎病變(IgA nephropathy)且病情有惡化風險的成人病人,用以減緩腎功能下降1,且無基線蛋白尿水平限製。這意味著耐賦康®作為全球首個且唯一獲得美國食品藥品監督管理局(FDA)完全批准的IgA腎病對因治療藥物,其覆蓋範圍進一步擴大,為更多中國IgA腎病患者帶來了新的希望。雲頂新耀首席執行官羅永慶表示:「耐賦康®在中國台灣的獲批,是今年耐賦康®繼在新加坡、中國香港獲批以及中國大陸首張處方落地之後的又一里程碑。在IgA腎病患者中,亞洲人群進展為終末期腎病的風險相較于其他人群高56%,且疾病進展更快,因此存在巨大未被滿足的臨床需求。未來,我們將繼續擴大耐賦康®在亞洲地區的可及性,以更好地滿足中國乃至亞洲更多IgA腎病患者迫切的臨床需求。」NefIgArd 3期全球臨床試驗結果顯示:與安慰劑相比,耐賦康®不僅帶來了持久的蛋白尿下降,減少鏡下血尿風險,更重要的是在估算腎小球濾過率(eGFR)上顯示出臨床相關且有統計學意義的治療獲益(p
More
正利控股推動建築業可持續發展與企業社會責任實踐 ACN Newswire

正利控股推動建築業可持續發展與企業社會責任實踐

香港, 2024年10月21日 - (亞太商訊 via SeaPRwire.com) - 隨著全球對可持續發展的重視,香港政府公佈《香港氣候行動藍圖 2050》,聯交所先後修訂,並將於2025年1月1日實施《ESG守則》,旨在加強上巿公司的環境管治及氣候信息透明度。在這一背景下,企業社會責任(CSR)及環境、社會及治理(ESG)已成為企業發展的重要基石,尤其是在香港的建築行業中,許多企業正積極推動這些努力,以展現對可持續未來的堅定承諾。首先,在職業健康與安全方面,許多公司始終將僱員的安全放在首位。例如,香港主板上市的建築公司正利控股有限公司(3728.HK),正在通過各種舉措推動企業社會責任和可持續發展。正利控股本年度參加了由香港中華廠商聯合會主辦的「ESG 約章」行動,獲得了第三方權威機構的認可。此舉旨在鞏固其在推廣和實踐ESG方面的領導地位。正利還承諾在未來降低工程及辦公室的能源消耗,並大力推動辦公室無紙化及內部環保政策。這不僅增強了企業的內部能力,還能在環保意識不斷提升的市場中贏得競爭優勢,推動企業的長期可持續發展。在工地場所,正利控股致力於提供安全的工作環境,並在建築工地定期進行應急演練。這不僅是企業的責任,更是對員工生命安全的尊重。此外,公司還重視增強僱員技能,培養未來的領袖。根據該集團年度報告的數據,僱員的培訓總時數達98.5小時,參訓比例高達約六成。這樣的培訓不僅提升了員工的專業技能,更讓員工意識到自身在社會環境中的重要角色。因為員工不僅是企業的生產力,更是環境保護和社會責任的參與者。某些公司在這方面的培訓體系,將員工的發展與企業的可持續發展目標緊密聯繫在一起,從而達到雙贏的效果。正利控股在推廣綠色建築技術方面也不遺餘力,公司要求所有員工在施工過程中嚴格遵守環保標準。例如,正利控股提倡使用可回收的建築材料,並在施工過程中最大限度地減少廢棄物產生。此外,該公司還積極推廣節能減排措施,如使用節能燈具和電動設備,以降低能源消耗。除了職業安全和技能培訓,企業在員工ESG方面還有其他舉措。例如,許多公司支持教育、醫療和文化等公益事業,並鼓勵員工參與社區服務。根據正利控股的年報數據,該公司在2023-2024財年向多個公益機構捐贈超過150萬港元,並有超過60名員工參與社區服務,這些行動彰顯了企業的社會參與。總體而言,對於環境及社會的探索之路,不僅僅是企業的責任,更是企業對員工的尊重和賦能。通過一系列的舉措,企業讓員工成為ESG的參與者,正利控股將企業的發展與員工的成長緊密聯繫在一起。這不僅是企業社會責任的體現,更是可持續發展的基石。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More

Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy

SHANGHAI, Oct 21, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON® indicated “to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression1”. There are no restrictions on initial proteinuria levels in the approved indication. This marks the expansion of NEFECON®, the world's first and only IgAN etiological treatment drug fully approved by the U.S. Food and Drug Administration (FDA), to more IgAN patients."The approval of NEFECON® in Taiwan, China is another milestone for NEFECON®, following approvals in Singapore, Hong Kong, and the commercial launch in Mainland China this year.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “IgAN is prevalent in the Asian population, which has 56% higher risk of progression to end-stage renal disease and faster disease progression, indicating a significant unmet clinical demand. In the future, we will continue to expand the access of NEFECON® across Asia to bring this first-in-disease therapy to more patients."The global Phase 3 NefIgArd clinical trial showed that compared to placebo, NEFECON® not only brought about a sustained reduction in proteinuria and reduced the frequency of microscopic hematuria but also demonstrated clinically relevant and statistically significant treatment benefits in estimated glomerular filtration rate (eGFR) (p
More
Ching Lee Holdings practices CSR to promote sustainability in the construction industry ACN Newswire

Ching Lee Holdings practices CSR to promote sustainability in the construction industry

HONG KONG, Oct 21, 2024 - (ACN Newswire via SeaPRwire.com) - With the increasing global emphasis on sustainability, the Hong Kong government has introduced the 'Hong Kong's Climate Action Plan 2050'. To enhance the transparency of environmental governance and climate-related disclosure for listed companies, HKEX has also revised the "ESG Code" to be effective from 1 January 2025. Within this evolving framework, Corporate Social Responsibility (CSR) and Environmental, Social, and Governance (ESG) factors have emerged as pivotal foundations for business development. This is particularly evident in Hong Kong's construction industry, where numerous companies proactively champion these initiatives to demonstrate a steadfast commitment to a sustainable future.As a good model among Hong Kong listed companies in construction industry, Ching Lee Holding Limited (3728. HK) is advancing its ESG agenda through a variety of initiatives. Notably, Ching Lee participated in the "ESG Pledge Scheme" this year organised and recognised by The Chinese Manufacturers' Association of Hong Kong. This initiative reinforces Ching Lee's leadership role in promoting ESG principles and highlights its proactive stance on sustainability.Employees' welfare and occupational health and safety are always the most important items on the ESG agenda. Ching Lee ensures preparedness on construction sites and conducts emergency drills regularly. This dedication reflects its responsible commitment and a profound respect for employee safety. Moreover, the company places a high value on enhancing employee skills. According to Ching Lee's annual report, the total training hours for employees reached an impressive 98.5 hours, with a training participation rate of approximately 60%. Employees are also integral participants in the ESG framework. Several companies have established training systems that align employee development closely with corporate sustainability objectives, thereby achieving a mutually beneficial outcome.In addition to prioritising occupational safety and skills training, Hong Kong companies support public welfare projects in education, healthcare, and culture, while encouraging employees to engage in community service. According to the annual report from Ching Lee Holdings, the company donated over HKD 1.5 million to various charitable organisations in the 2023-2024 financial year, with more than 60 employees actively participating in community service. Furthermore, Ching Lee commits to promoting green building technologies and mandates that all employees adhere rigorously to environmental standards throughout construction. For instance, the company advocates for using recyclable building materials and strives to minimise waste generation during construction activities in addition to energy-saving and emission-reduction measures.By implementing a comprehensive range of initiatives, Hong Kong companies enable their workforce to become active participants in ESG efforts. Ching Lee Holdings adeptly links corporate development with employee growth, illustrating that corporate social responsibility is not merely essential but constitutes a fundamental pillar of sustainable development. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Moolec Has Received USDA Approval for the First Genetically Modified Pea in History ACN Newswire

Moolec Has Received USDA Approval for the First Genetically Modified Pea in History

Luxembourg, Oct 16, 2024 - (ACN Newswire via SeaPRwire.com) - Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance from USDA-APHIS achieved by Moolec in an 18-month window, alongside its genetically engineered safflower and soybean for GLASO™ and Piggy Sooy™ products, respectively. Access the official USDA-APHIS publication here."With USDA approval for our GE pea, Moolec has now secured regulatory clearance for all of our key crops in the US: safflower, soybean, and pea," said Gastón Paladini, CEO and Co-Founder of Moolec. "We are proud to be the only Molecular Farming company with three US regulatory approvals and a major commercial contract. This milestone underscores our leadership in the landscape with tangible, science-backed results."Moolec's genetically engineered peas produce high yields of bovine myoglobin, a protein that boosts iron content, making it an ideal alternative for consumers seeking plant-based sources of iron. This product has the potential to revolutionize both the food ingredient market and the $65 billion pea industry by offering a nutritious, iron-rich alternative to traditional meat products.Amit Dhingra, Chief Science Officer for the Company, stated, "The USDA-APHIS Regulatory Status Review for pea marks a significant milestone for Moolec. As the first review for GE pea, it represents a historic development. It validates Moolec's strategic approach and exemplifies our commitment advancing sustainable food production through science and innovation. This approval is a critical step toward enhancing global food supply and meeting the growing demand for innovative, nutritious food solutions for the world."This approval not only showcases Moolec's innovation in Molecular Farming but also highlights the company's commitment to meeting the highest regulatory and safety standards. Moolec has also developed an Identity Preservation Program to ensure sustainable farming practices, promote stewardship for its crops and product quality for partners, clients and consumers alike.According to USDA-APHIS regulation found at 7 CFR part 340, developers may submit a request for a RSR when they believe a GE plant is not subject to the regulation. APHIS reviews the GE plant and considers whether it might pose an increased plant pest risk compared to its non-GE comparator. If APHIS does not identify a greater pest risk relative to the comparator, the GE plant is not subject to this regulation. Regulation 7 CFR part 340 governs the importation, interstate movement, and the environmental release of certain organisms that have been modified or produced by genetic engineering.The USDA-APHIS review process is a critical component of ensuring that genetically engineered crops can be grown safely, and this approval opens the floor for expanded field trials, seed scaling, and eventual commercialization. With increasing interest in science-based ingredients, this approval positions the company to lead a new wave of innovation in the food and agriculture sectors.About Moolec Science SAMoolec is a science-based ingredient company leader in the use of Molecular Farming technology for food and dietary supplementation markets. The Company's mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal proteins for the good of the planet. Moolec's technological approach aims to have the cost structure of plant-based solutions with the nutrition and functionality of animal-based ones. Moolec's technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company's product portfolio and pipeline leverage the agronomic efficiency of broadly used target crops like soybean, pea, and safflower to produce oils and proteins. Moolec also has an industrial and commercial R&D capability to complement the company's Molecular Farming technology. Moolec secures a growing international patent portfolio (25+, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of PhDs and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit moolecscience.com and ir.moolecscience.com.Forward-Looking StatementsThis publication contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this publication, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this publication will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Contact InformationPress & Mediacomms@moolecscience.comInvestor Relationsir@moolecscience.comRelated FilesMoolec Has Received USDA Approval For The First Genetically Modified Pea In HistorySOURCE: Moolec Science Copyright 2024 ACN Newswire via SeaPRwire.com.
More
中信國際電訊CPC 成就「+AI到AI+」實現「技術賦能」結合「數據賦能」 ACN Newswire

中信國際電訊CPC 成就「+AI到AI+」實現「技術賦能」結合「數據賦能」

香港, 2024年10月18日 - (亞太商訊 via SeaPRwire.com) - 中信國際電訊集團有限公司(「中信國際電訊」,香港交易所股份代號:1883)全資擁有的中信國際電訊(信息技術) 有限公司(「中信國際電訊CPC」) 站在AI+創新發展前沿,實現技術與數據雙賦能 ,推動產業鏈智能化升级新模式。中信國際電訊CPC進一步啟動多個人工智能+項目落地,透過智能化升級'智賦雲網安'底座;匯聚AI 技術、 大數據分析及信息安全交互能力,深入行業場景,融合智能應用賦能千行百業,重塑企業智能營運之旅。中信國際電訊CPC 攜手夥伴共築AI+ 生態圈從'技術賦能(+AI)'到'數據賦能(AI+)'人工智能(AI)在現今商業環境不可或缺,作為世界一流的數智通訊服務供應商,中信國際電訊CPC前瞻部署了面向未來的創新策略'ICT-MiiND / ICT-智賦'。更將'創新'技術、算力算法和大數據元素全棧無縫融合到ICT服務平台中,全面擁抱全球生成式AI時代,夯實智賦雲網安。中信國際電訊CPC深信AI+的變革力量,積極投入AI技術和AIOps模塊增强'智能'元素,聚焦從'大模型建設'到'小場景落地'能力,提升與各行業深度融合。中信國際電訊CPC不僅部署了豐富的AI技術資源,更通過深度整合生成式AI應用開發的全鏈條技術模塊、實踐由技術賦能(+AI )數智化應用模式,演化成數據賦能(AI+)新篇章。AI+不但涵蓋多元 AI 技術及應用,更融合大數據平台與小場景模型;從數據收集、儲存、治理、挖掘,通過深度算法、機器學習與智能分析,提煉出一系列數智應用場景與AI+ 解決方案。圍繞企業需求適配,提供從業務轉型到戰略解碼,再到運營提升的一站式服務,全方位滿足企業需求。中信國際電訊CPC行政總裁黃政華先生表示:「中信國際電訊 CPC致力將AI大模型與多元AI+應用小場景應用融合,助力客戶創增數智動能,實現更多可能!」中信國際電訊 CPC 行政總裁黃政華先生表示:「從+AI到AI+新模式,中信國際電訊 CPC作為業界AI技術先行者,一直秉持'創新‧不斷'研發多元智能技術,持續優化'雲網智安'解決方案,提速數智化賦能產業發展。我們積極投放資源,攜手夥伴共築繁榮AI+ 生態圈,豐富技術底座,引領客戶及行業走向以大語言模型,AI技術、智能分析及數據驅動的生成式AI年代;致力將AI大模型與多元AI+應用小場景應用融合,助力客戶創增數智動能,實現更多可能!」變革性的AI+解決方案 賦予數據及信息安全應用場景新動能中信國際電訊CPC站在AI技術的前沿,憑藉二十多年ICT的專業經驗和行業知識, 其數據科學和創新團隊在人工智能領域持續發力,以創新算法及深度學習技術釋放數據價值,更積累了大量生成式AI案例在企業端應用實踐,為企業降本增效。一系列屢獲殊榮的AI+解決方案中包括最新的AI Databank (智數庫)及AI Pentest (滲透測試)。- AI Databank (智數庫) - 大數據平台、智能化分析 | 更快、更準、更科學AI Databank (智數庫) 透過整合多個系統,收集內外信息 (如客服管理及營運日誌等)的海量數據,利用生成式AI技術,經過深度學習與大數據訓練,提供數據管理,即時生成報表。並可透過大型語言模型技術驅動的智慧分析功能,讓用戶以對話式界面與平台互動,快速檢索資料及生成各種可視化圖表,從而提煉數據驅動的商業價值。此外,更可通過分析當前及歷史數據,構建預測模版,助力企業規劃未來。- 革新自動AI Pentest (滲透測試)|更主動、更安全、更智能中信國際電訊CPC自去年底推出的'TrustCSI™ 3.0雲網神盾'網絡安全解決方案,成功引領安全運作中心(SOC)進入AI驅動的新時代。最新的AI Pentest滲透測試,更在整個方案中發揮關鍵作用。AI滲透測試是一項輕量級解決方案,採用獨特的 AI驅動技術,有效揭示網站應用程式防火牆(WAF)的弱點,並實現自動化的例行任務調度,以簡化內部網絡資產漏洞評估流程。AI滲透測試如同網絡AI掃地機器人,24x7全自動化運作,協助企業找出網絡中的關鍵漏洞,建立強大的主動式防禦機制 。中信國際電訊CPC的AI+方案落地於千行百業,推動AI+應用向多元場景發展AI+數智化產業新模式 為千行百業創優增值中信國際電訊CPC的AI+方案落地於千行百業,推動AI+應用向多元場景發展,協助産業鏈將生成式AI技術,深度學習及數據應用全棧融合業務,為企業數字化轉型之旅賦能,當中包括:- AI+電訊業中信國際電訊CPC以AI+創新能力打造「網絡與信息安全威脅識別算法模型」,憑藉自然語言處理,算法模型與創新技術架構,構建'AI+電訊產業'應用平台,利用人工智能安全行業大模型學習和識別騷擾,以及詐騙電話的模式與特徵 ,對大量已知騷擾及詐騙電話資料進行預學習,知識解構和深度訓練,自動學習識別網絡中即時出現新的騷擾或詐騙電話,大幅提高分析及攔截準確率,為社會締造價值。用戶個案: 中信國際電訊自主研發的'AI+跨境移動通信網絡安全管理平台'項目,獲得市場上多個重量級獎項。項目通過提供語音/信令/短信防火牆攔截,助力各主要電訊業界、流動服務營運商及企業客户實時預警及攔截非法欺詐語音/短信。平台採用雲端架構 ,應用於本地及跨境跨網場景,識別從國際到中國內地、國際與國際之間的通訊,方案有效協助市民識別已獲認證的短信發送人,以打擊涉及冒充其他公司或機構身分發出短信行騙。- AI+製造業製造業全球發展迅速,與新技術融合的動力與日俱增,在AI的引領下,企業積極綜合運用多種AI 工具、多元應用場景和大數據等創新技術,構建革新數智化生態系統。產業鏈不僅提高生産效率和質量,通過數字規劃和智能分析,能高效響應變化,並可更精準做好未來運營規劃。加持AI驅動信息安全解決方案,更為企業安全威脅監測提供即時回應,加強數據及信息安全保障,鍛造出更安全、更智能的製造環境,助力智能生産領域全面升級。用戶個案:中信戴卡是全球鋁車輪行業首家'燈塔工廠',在其數智化建設過程中,中信國際電訊CPC聯同子公司中企通信扮演了至關重要的角色,為其搭建了安全、高效、快速的數據高速公路,網絡不僅覆蓋了廣泛的國際區域,還有效地促進了中信戴卡全球各工廠之間的互聯互通,並助力其顯著提升了數智化運營管理水平。創新團隊憑藉深厚的行業洞察與技術實力,助力中信戴卡在AI視覺賦能製造、AI賦能工藝優化、AI賦能研發設計、AI賦能營運決策、AI賦能綠色低碳等多個應用場景克服網絡和安全等方面的挑戰,助力構建'鋁製汽車零部件垂直行業大模型',進一步提高了生產效率和智能化水平。智賦雲網安平台不僅為中信戴卡的全產業鏈智能升級提供了有力保障,更夯實了其AI+安全'能力,通過自動化威脅監測與高效實時的回應警報,築牢信息安全底座,鍛造'燈塔工廠'新輝煌。- AI+汽車業需求預測是企業供應鏈數字化、智能化轉型佈局中最重要的一環。中信國際電訊CPC'訂單需求智慧預測專案解決方案',應用AI技術為零散物料供應鏈提供精準數據分析,提升車型訂單需求的預測準確率 ,動態調節物料及產能規劃。用戶個案:總部位于歐洲的世界知名的汽車零件供應商,業務分佈在29個國家地區,服務全球眾多知名汽車品牌。中信國際電訊CPC賦能客戶打造'訂單需求智慧預測專案解決方案',提升預測準確率達80%以上,優化供應鏈管理, 實現降本增效。- AI+零售業零售業處於人工智能大規模落地應用水平。中信國際電訊CPC一體化'雲網智安'解决方案協助企業構建安全、高效及靈活的數智基礎設施,更透過對網絡及應用的動態感知、預測及智慧預警,提升網絡傳輸、信息安全、雲端運算資源及AI平台的能力。配合AI技術與數據分析助力企業提早數智化部署,在傳統工作流設計模式的基礎上增加場景模版,如客服管理、研發評審和營銷報告等場景,利用大數據規劃策略以贏得市場先機。用戶個案:國際知名化妝零售品牌多年來致力於科研與創新,憑藉中信國際電訊CPC'智賦雲網安'綜合方案,協助構建安全、高效及靈活的數字基建底座,通過對網絡及應用的動態感知、預測及智慧預警,助力實現「在上海、為中國、鏈全球」的優勢價值,滿足其中國內地以至世界各地消費者的需求。如欲了解更多有關從'技術賦能(+AI)'到'數據賦能(AI+)',請瀏覽:https://www.citictel-cpc.com/zh-hk/ict-miind中信國際電訊CPC簡介中信國際電訊(信息技術)有限公司(「中信國際電訊CPC」)是中信國際電訊集團有限公司(香港交易所股份代號:1883)的全資附屬公司,一直矢志透過先進技術及旗艦解決方案,包括TrueCONNECT™專用網絡服務、TrustCSI™信息安全解決方案、DataHOUSE™全球統一雲數據中心解決方案及SmartCLOUD™雲端運算解決方案,為全球跨國企業提供綜合數碼解決方案, 滿足不同行業的ICT服務需求。憑借「創新‧不斷」的服務理念,中信國際電訊CPC積極利用創新技術,提煉'技術賦能',將人工智能、擴增實境、大數據,物聯網和其他尖端新興技術,融合深度學習及智能數據分析技術,轉化為'數據賦能'生成式AI+應用,重塑企業智能營運之旅。中信國際電訊CPC以「服務在地,連接全球」的優勢,承諾為客戶提供最優質的一站式ICT服務。全球化網絡資源連接近170個服務據點、60多個SDWAN 網關;21個雲服務中心、30多個數據中心及3個全天候運作的安全運作中心,服務遍布约160個國家和地區,無縫連接亞洲、歐美、非洲、中東以及中亞等地區 。透過全球化服務佈局,多年不斷深耕各個行業與領域經驗,一系列國際認證(SD-WAN Ready, ISO 9001、14001、20000、27001 及27017),確保為企業提供國際化標準及專業在地服務能力,成為客戶信賴的信息智能化服務供應商。請瀏覽 www.citictel-cpc.com獲取更多資訊。傳媒查詢:Catherine Yuen中信國際電訊CPC(852) 2170 7536 電郵:catherine.yuen@citictel-cpc.com Copyright 2024 亞太商訊 via SeaPRwire.com.
More
CITIC Telecom CPC Propels ‘+AI to AI+’ ACN Newswire

CITIC Telecom CPC Propels ‘+AI to AI+’

HONG KONG, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is at the forefront of AI+ innovation era, enabling dual empowerment of technology and data, and fostering a new business model of intelligence and innovation across industries. CITIC Telecom CPC has further unleashed multiple AI+ projects powered by “AI+ Cloud, Network, Security” framework, the integration of AI technology with big data analytics and security capabilities, and vital customer experience, fueling innovative AI+ applications across industries to reshape the Intelligence Operation Journey of enterprises.CITIC Telecom CPC collaborates with partners to co-create AI+ EcosystemFrom “Technology Empowerment”(+AI) to “Data Empowerment” (AI+)AI has become a cornerstone in today’s business landscape. As a leading Global-Local Intelligent DICT Service Partner, CITIC Telecom CPC fully embraces the global digitalization era and proactively deploys the visionary “ICT-MiiND” framework. This framework seamlessly integrates an “innovative” technology stack, the power of algorithms and big data into the ICT service platform, spanning across “Cloud, Network, Security” and bolstering the element of “intelligence” through cutting-edge AI technology and AIOps modules. CITIC Telecom CPC believes in the transformative power of AI+, actively enhances the in-depth integration of AI across various industries, driving innovative projects from focusing on "Big Data Modelling" to "Small-Scale Scenario implementation". CITIC Telecom CPC has not only deployed extensive resources in AI technologies, but also deeply integrated generative AI applications across the full-chain technology modules, evolving from Technology Empowerment (+AI) to Data Empowerment (AI+), ushering in a new era driven by AI algorithms and big data. AI+ covers diverse AI technologies and applications, integrating big data platforms with small-scale scenario models. This approach covers data collection, storage, governance and mining through deep algorithms, machine learning, and intelligent analysis, to develop a range of intelligent applications and AI+ solutions. Tailored to meet enterprise needs, it provides a one-stop service from business transformation to strategic analysis, efficiently fulfilling enterprise requirements.“CITIC Telecom CPC strives to integrate large AI models with diverse AI+ applications in small-scale scenarios, empowering customers to advance intelligent capabilities, unlocking a realm of new possibilities,” said Mr. Brook Wong, CEO of CITIC Telecom CPCMr. Brook Wong, Chief Executive Officer of CITIC Telecom CPC, said, “Striding from +AI to AI+, CITIC Telecom CPC pioneers AI technologies with a steadfast commitment to ‘Innovation Never Stops', continuously optimizes “Cloud, Network, Intelligence, Security” "solutions, and accelerates the development of intelligence-enabled industries. We actively dedicate various resources and collaborate with partners to co-create a prosperous AI+ ecosystem, enrich technical infrastructure, lead our team and the industry towards a generative AI era driven by large language models, AI technologies, data and intelligent analysis. We strive to integrate large AI models with diverse AI+ applications in small-scale scenarios, empowering customers to advance intelligent capabilities, unlocking a realm of new possibilities.”Transformative AI+ Solutions Generate New Driving Force for Data & Security ApplicationsCITIC Telecom CPC stands at the forefront of AI technology. With decades of ICT experience and industry expertise, its data science and innovation teams are propelling AI innovations with cutting-edge algorithms and deep learning techniques, unlocking data value and accumulating a range of generative AI applications for enterprises. The team has developed a series of award-winning and groundbreaking AI+ solutions such as the newly-launched AI Databank and AI Pentest, driving operational efficiency and cost savings for enterprises.AI Databank – Powering Big Data with Fast, Accurate & Actionable Insights on a Single PlatformAI Databank integrates tremendous data from various business systems, collecting a wide array of internal and external information (such as CRM and ERP). Utilizing generative AI technology, enhanced by deep learning and big data training, it enables efficient data management and real-time report generation. Users can interact with the platform to quickly retrieve data and multiple real-time data charts through dialog-based data queries, empowering data-driven decision making. AI Databank also analyzes current and historical data to build forecast models, helping companies in future planning.AI Pentest – Redefining Vulnerability Assessment with Proactive, Secure and Intelligent AutomationCITIC Telecom CPC has successfully led the Security Operations Center (SOC) to enter into a new AI-driven era since the launch of "TrustCSI™ 3.0" cybersecurity solution at the end of last year. The newly-launched AI Pentest plays a key role in the security portfolio. It is a lightweight solution powered by unique AI-driven bypass techniques to expose WAF vulnerabilities, enabling automated routine task scheduling to simplify the assessment of internal network asset and empower enterprises to keep pace with the rapidly changing IT environment. AI Pentest functions as an AI robot cleaner which automatically operates 24x7, helping enterprises identify key vulnerabilities in the network and establish a robust defense against potential threats.CITIC Telecom CPC's AI+ solutions have been implemented in various industries to foster integration of diverse AI+ applicationsAI+ Reshapes Industries with New Scenarios & Business ValuesCITIC Telecom CPC's AI+ solutions have been implemented in various industries to foster integration of diverse AI+ applications, assisting customers in incorporating generative AI technology, deep learning and data applications, empowering digital transformation for enterprises including:- AI+TelecommunicationsCITIC Telecom CPC leverages AI+ innovation capabilities to create a "Network and Information Security Threats Identification Algorithm Model". Leveraging Natural Language Processing (NLP), algorithm models and innovative technical architecture, an "AI+ telecommunications industry" application platform is created. The platform uses large AI security industry models to learn and identify scams as well as the patterns and characteristics of fraudulent calls. A repetitive learning and training cycle, integrated deep learning capability, on a large amount of known scams and fraudulent calls data is conducted to automatically identify new suspicious calls in the network immediately, greatly improving the accuracy of analysis and interception, and generating values for the society.Use case: Developed by CITIC Telecom, “AI+ Digital and Intelligent Cross-border Mobile Network Security Service Platform” project has won multiple distinguished awards in the market. The project utilizes Voice/Signaling/SMS firewall interception to help major telecommunications service providers, mobile service operators and enterprise sector to enable real-time alerts and interception of illegal and fraudulent Voice/SMS messages. The cloud-based platform can be utilized in local and cross-border cross-network scenarios to identify SMS messages from international countries to mainland China and inter-country communications. The solution effectively helps citizens identify registered SMS senders to stop fraudsters from sending scam SMS messages masquerading as other companies or organizations.- AI+ ManufacturingAs the global manufacturing industry is booming rapidly, the integration with different new technologies is accelerating. Powered by AI, enterprises actively deploy multiple AI tools, diverse application scenarios and big data to build an innovative digital and intelligence ecosystem. Industry chain not only enhances production efficiency and quality, but also responds to changes efficiently through digital planning and intelligent analysis, and also devises more precise future operations plans. AI-driven data security solutions provide enterprises with instant responses to security threats,enhanced data and cyber security, secure and intelligent manufacturing environment, elevating intelligent production to a new level.Use case: CITIC Dicastal, the first lighthouse factory in the global aluminum wheel industry, paved the way for its transformation journey with pivotal support from CITIC Telecom CPC and its subsidiary China Entercom in establishing a secure, efficient and fast data highway. This initiative enabled seamless connectivity among its global factories and significantly enhanced its digital and intelligent operational management capabilities. Leveraging its industry expertise, insights and technical knowledge, CITIC Telecom CPC’s Innovation team empowered CITIC Dicastal to overcome networking and security challenges across various application scenarios, including AI-driven manufacturing, process optimization, R&D design, operational decision-making, green and low-carbon initiatives, facilitating to build a “Vertical Industry Big Model of Aluminum Automobile Parts”, enhancing production efficiency and intelligence. CITIC Telecom CPC’s “AI+ Cloud, Network, Security” not only empowers the intelligent enhancement of CITIC Dicastal's entire industry chain but also reinforces its "AI+ Security" capabilities, refines real-time response alerts and develops interconnection across global factories while effectively monitoring information security threats. These initiatives strengthen the cornerstone of information security, forging a new era for the “Lighthouse Factory”. - AI+ AutomobileDemand forecasting is the most important part of the digital and intelligent transformation of an enterprise's supply chain. CITIC Telecom CPC's "Intelligent Order Demand Forecasting Solution" utilizes AI technology to predict complex and fragmented materials, improving the forecasting accuracy of order demand for vehicle models, and dynamically adjusting materials and production capacity planning.Use case: Headquartered in Europe, a world-renowned automobile parts supplier operates in 29 countries and regions, and serves various well-known automobile brands around the world. CITIC Telecom CPC’s "Intelligent Order Forecast Solution" enables customers to increase forecast accuracy to over 80%, optimize supply chain management, and achieve cost reduction and efficiency improvement.- AI+ RetailThe retail industry is undergoing a large-scale implementation of AI applications. CITIC Telecom CPC's “Cloud, Network, Intelligence, Security” integrated platform help enterprises build a secure, efficient and flexible digital infrastructure, enhance network transmission, information security, cloud computing resources and AI platform capabilities through dynamic perception, predictions and intelligent alerts for networks and applications. Harnessing AI technology and data analysis, we facilitate enterprises in expediting their digital transformation. By enhancing traditional workflow designs with scenario templates like customer service management, R&D evaluation, and marketing reports, strategically utilize big data to reinvent business to seize market opportunities.Use case: A world-renowned cosmetics retail brand has been committed to scientific research and innovation for many years. CITIC Telecom CPC's “AI+ Cloud, Network, Security” integrated platform helps to build a secure, efficient and flexible digital infrastructure. The dynamic perception of networks and applications, predictions and intelligent alerts for networks and applications assist the cosmetics retail brand to realize the values of “In Shanghai, For China, and Connect the World" to meet the needs of consumers in mainland China and around the world.To know more information aboutFrom “Technology Empowerment” (+AI) to “Data Empowerment” (AI+),please visit https://www.citictel-cpc.com/en-hk/ict-miindAbout CITIC Telecom CPCWe are CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT™ private network solutions, TrustCSI™ information security solutions, DataHOUSE™ cloud data center solutions, and SmartCLOUD™ cloud computing solutions.With the motto “Innovation Never Stops,” we leverage innovative technologies to boost technology empowerment (+AI). Embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies we aim to unlock technical potential. By integrating deep learning and intelligent data analysis technologies, we transform these technologies into data empowerment (AI+) generative applications, reshaping the Intelligence Operation Journey of enterprises.With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across nearly 160 countries and regions, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect nearly 170 points of presence (POPs), 60+ SDWAN gateways, 21 Cloud service centers, 30+ data centers, and three dedicated 24x7 Security Operations Centers (SOCs). We are certified with a series of international certifications, including SD-WAN Ready, ISO 9001, 14001, 20000, 27001, and 27017, to ensure our services compliance with international standards and resources for enterprises. We offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers.For more information, please visit www.citictel-cpc.comMedia Contacts:Catherine YuenCITIC Telecom CPC(852) 2170 7536Email: catherine.yuen@citictel-cpc.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More

雲頂新耀股價升兩成 盈利潛力助力估值修復

香港, 2024年10月18日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀(1952.HK)今日收盤升20.46%,最高觸及28.6港元,公司自公佈中期業績開始股價一路向好,今日成交額達2.91億元。消息層面看到,交銀國際發表報告稱,予內地醫藥行業「領先」評級,其中重點推薦了雲頂新耀等一眾股票。近期香港政府發佈施政報告,眾多舉措有助吸引海外資金來港,對港股市場有推動作用,另外創新藥板塊負面情緒逐漸褪去,市場開始關注有盈利潛力和估值具有修復彈性的創新藥標的。根據雲頂新耀2024年中期財報,公司上半年收入大幅增長至人民幣3.02億元,較去年下半年增長158%,並實現公司歷史上的首次商業化盈利。目前,公司的核心產品耐賦康®和全球首個氟環素類抗菌藥物依嘉®(XERAVA®)已實現商業化,預計到年底將有三款產品實現商業化上市。在創新研發方面,雲頂新耀擁有一個具有全部智慧財產權及全球權益的mRNA平台,用來開發預防及治療性的mRNA自研產品。公司預計於2024年實現全年人民幣7億元的銷售目標,並力爭在2025年底前實現現金盈虧平衡。交銀國際最新發表報告表示,短期催化劑豐富、盈利高增長或盈虧平衡時間點明確、估值有較大修復彈性的創新藥標的,以及市值與基本面偏離較大的中小型創新藥企,流動性改善後的反彈彈性將十分可觀。近两个月来,云顶新耀的股价一度累计涨超65%。消息面上,近期国内货币政策的超预期调整激发了资本市场的活力,港A两地股市持续上涨。其中,创新药板块因其长期估值筑底和极具增长潜力的特性,拥有较高的投资性价比,成为此轮行情中值得关注的重要方向之一。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More

Everest Medicines’ Stock Price Rises by 20% as Profit Potential Drives Valuation Recovery

HONG KONG, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (1952.HK) closed today with a 20.46% increase, hitting a high of HKD 28.6. The company's stock price has been steadily rising since the release of its interim results, with today's trading volume reaching HKD 291 million. Market updates show that BOCOM International released a report assigning an 'outperform' rating to the Chinese pharmaceutical sector, with Everest Medicines being one of the key recommended stocks.Recently, the Hong Kong government released a policy address with numerous measures aimed at attracting overseas capital to Hong Kong, which has been a positive driver for the Hong Kong stock market. Additionally, negative sentiment in the innovative drug sector is gradually fading, and the market is now focusing on companies with profit potential and valuation recovery resilience.According to Everest Medicines' 2024 interim financial report, the company saw a significant revenue increase in the first half of the year, reaching RMB 302 million, representing a 158% growth compared to the second half of last year, marking the first time the company has achieved commercial profitability. The company's core products, Nefecon® and XERAVA® (the world's first-in-class fluorocycline antibiotic), have already been commercialized, with three products expected to be launched by the end of the year. In terms of innovative research and development, Everest Medicines owns an mRNA platform with full intellectual property rights and global benefits, dedicated to developing both preventive and therapeutic mRNA products. The company expects to achieve full-year sales of RMB 700 million by 2024 and aims to break even by the end of 2025.As BOCOM International released a report, it highlighted that innovative drug companies with abundant short-term catalysts, strong profit growth potential, or clear break-even timelines, along with significant valuation recovery potential, are worth close attention. Investors are also advised to focus on small and mid-sized innovative pharmaceutical companies whose market value diverges significantly from their fundamentals. These companies are expected to experience a strong rebound as liquidity improves.Over the past two months, Everest Medicines' stock has risen by over 65%. Recently, the unexpected adjustments in domestic monetary policy further energized capital markets. The continuous rise in both Hong Kong and mainland Chinese stock markets highlights the innovative drug sector as a key area of focus, given its long-term valuation bottoming and significant growth potential, making it a highly attractive investment in this market rally. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
The 15th Turkish-Arab Economic Forum (TAFF 2024) took place at the Four Seasons Bosphorus Hotel in Istanbul ACN Newswire

The 15th Turkish-Arab Economic Forum (TAFF 2024) took place at the Four Seasons Bosphorus Hotel in Istanbul

ISTANBUL, October 18, 2024 - (ACN Newswire via SeaPRwire.com) - The 15th Turkish-Arab Economic Forum (TAFF 2024), aimed at deepening relations between Turkiye and the Gulf countries and defining joint strategies for the region, took place yesterday in Istanbul.The Forum saw the attendance of many key figures from the Gulf countries, including Kuwait's Minister of Finance Noora Suleiman Salem Al-Fassam, Iraq's Minister of Finance Taif Sami Mohammed, Egypt's Deputy Minister of Finance Ahmed Kouchouk, Tunisia's Minister of Economy and Planning Samir Abdelhafidh, Libya's Minister of Finance Dr Kalid Al-Mabrouk, President of the Turkish Investment Fund Baghdad Amreyev, Secretary General of the Egyptian Federation of Arab Chambers Dr Khaled Hanafy, Regional Director of the Saudi International Finance Corporation Fawaz Bilbeisi, Director of the World Bank GCC Cooperation Safaa El Tayeb El-Kogali, Partner at the UK's DWF Solomon Ebere, Board Member of the Qatar Chamber Mohamed Bin Ahmed Al Obaidly, and Vice President of International Business Development of the United Arab Emirates Khalid Al Marzooqi.Turkiye's Minister of Treasury and Finance Mehmet Simsek evaluated global and regional strategies.In his speech at the 15th Turkish-Arab Economic Forum, Minister of Treasury and Finance Mehmet Simsek highlighted the decline in inflation and the slowdown in monetary policies. He emphasized that global trade will continue in November, pointing out that while there are challenges, there are also opportunities in this process. Mehmet Simsek further noted that he expects an increase in cooperation across various sectors, emphasizing that partnerships in energy, manufacturing, technology, and machinery are crucial for realizing the region's potential and he expressed his support for diversification strategies.Dr. Erkan Kork stated that Turkiye and the Gulf countries could build a shared future.Speaking at the 15th Turkish-Arab Economic Forum, Dr. Erkan Kork, Chairman of the Board of BankPozitif, highlighted that the participating countries share the same geography, history, and values, and emphasized that joint steps would be stronger and more effective. He noted that building a shared future with the available know-how, technology, and investments is vital for unlocking the region's potential.BankPozitif Chairman Dr Erkan Kork at the 15th Turkish Arab Economic ForumExpressing pride in Turkiye's positioning as a fintech hub, Dr Erkan Kork predicted that Turkiye would play a leading role on the global stage in various fields in the near future. He also stressed the importance of forums, fairs and events like this for fostering relationships between the business world and governments of different countries.In his speech, Dr Erkan Kork pointed out that Turkiye is in a very strong position in terms of innovation and information technology, noting that while processing times in many sectors in Europe are long, they are much shorter in Turkiye. Dr. Erkan Kork also highlighted Turkiye's high level of competitiveness in recent years.At the forum, which had a high participation rate, Fatih Karahan, Governor of the Central Bank of the Republic of Turkiye, Burak Dagloglu, Member of the Board of Directors of the Turkiye Wealth Fund, and Rfat Hisarckloglu, President of the Union of Chambers and Commodity Exchanges of Turkiye, were also among the speakers.Source: BankPozitif, https://www.bankpozitif.com.trSait Inanc, +90533 722 49 69, info@bankpozitif.com.tr* This press release is issued through EuropeNewswire.Net (www.europenewswire.net) and distributed by EmailWire (www.emailwire.com) – the gloabal newswire that provide Press Release Distribution with Guaranteed Results™. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
康哲藥業:蘆可替尼乳膏(白癜風)大灣區首批處方落地 ACN Newswire

康哲藥業:蘆可替尼乳膏(白癜風)大灣區首批處方落地

深圳, 2024年10月18日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司(「康哲藥業」)欣然宣佈,磷酸蘆可替尼乳膏(「蘆可替尼乳膏」或「產品」)在中山陳星海中西醫結合醫院、佛山複星禪誠醫院、以及東莞松山湖東華醫院為符合條件的白癜風患者開出大灣區首批處方。產品於2024年4月11日獲得澳門政府藥物監督管理局(ISAF)批准新藥上市申請,隨後通過「港澳藥械通」政策,並於8月19日獲得廣東省藥品監督管理局批准,正式落地粵港澳大灣區內地指定醫療機構,用於12歲及以上青少年和成人患者伴面部受累的非節段型白癜風的治療,為相關適應症患者提供了全新治療選擇。此外,蘆可替尼乳膏白癜風適應症新藥上市許可申請已於9月24日獲得中國國家藥品監督管理局(NMPA)受理。根據海南博鰲樂城國際醫療旅遊先行區藥品真實世界數據應用試點程式有關規定,蘆可替尼乳膏在中國開展真實世界研究,療效積極,與境外關鍵臨床研究結果一致。所有的次要療效指標均顯示出與主要療效指標一致的獲益趨勢,且治療時間越長,患者的白癜風治療效果持續改善。同時利用了樂城先行區安全監測數據,未發現新的安全性事件。不良反應的嚴重程度大部分均為1級或2級,未發生導致停藥或退出的不良事件(AE),未發生研究藥物相關的嚴重不良事件(SAE)。若產品於中國大陸獲批上市,其有望成為首個經NMPA批准用於白癜風複色的處方藥,將為中國廣大白癜風患者帶來治療新曙光。除上述進展外,產品此前於2023年8月12日獲得海南省藥監局批準臨床急需進口,並於8月18日正式落地海南博鰲樂城國際醫療旅遊先行區,用於12歲及以上青少年和成人患者伴面部受累的非節段型白癜風的局部治療。受益于國家賦予海南自由貿易港、博鰲樂城國際醫療旅遊先行區「先行先試」特許政策,中國白癜風患者可在博鰲超級醫院先行申請使用產品並接受專家團隊的治療。截至2024年6月30日,已有超3,200例患者在博鰲超級醫院使用蘆可替尼乳膏進行治療。康哲藥業始終以患者為中心,以臨床需求驅動創新,為提升藥物可及性而持續努力。本次蘆可替尼乳膏得益於「港澳藥械通」政策支持,先行獲批引入大灣區,並完成首批處方落地,縮短了中國白癜風患者使用創新藥的用藥時差,讓更多國內白癜風患者獲益。展望未來,康哲藥業將繼續為滿足中國患者未盡之需而奮進,持續挖掘國際品質的新藥、好藥,高效推動產品臨床開發和商業化發展,以差異化的創新突破為病患帶來更多優質的醫藥產品,為守護患者健康生活和生命質量貢獻力量。關於蘆可替尼乳膏蘆可替尼乳膏(Opzelura),為Incyte的JAK1/JAK2選擇性抑制劑蘆可替尼的創新乳膏製劑,已獲得美國食品和藥物管理局(FDA)批準用於12歲及以上非節段型白癜風患者的局部治療。截至目前,蘆可替尼乳膏是首個也是唯一一種在美國獲批使用的白癜風複色產品[1]。此外,產品在美國獲批用於傳統外用處方療法不可取或不能充分控制病情之12歲及以上非免疫功能低下的輕中度AD患者的局部短期和非持續性慢性治療[2]。產品也於歐洲獲批用於12歲及以上青少年及成人患者伴面部受累的非節段型白癜風的治療[3]。康哲藥業於2022年12月2日,通過其附屬公司-康哲美麗與Incyte就用於治療自身免疫性炎症皮膚病的蘆可替尼乳膏製劑訂立合作和許可協議(「許可協議」)。根據該等許可協議,康哲藥業通過康哲美麗獲得在中國大陸、香港特別行政區、澳門特別行政區、台灣地區及東南亞十一國(印尼、菲律賓、越南、泰國、緬甸、馬來西亞、柬埔寨、老撾、新加坡、東帝汶以及文萊)(「區域」)開發、註冊及商業化產品的獨家許可權利,以及在區域內生產產品的非獨家許可權利。許可協議期限開始於許可協議生效日,自產品在區域內首次商業化銷售之日起擁有十年的授權期限(「授權期限」)。授權期限屆滿後,根據許可協議約定的特定條件,許可協議期限可延長十年(「初始延展授權期限」)。初始延展授權期限屆滿後,根據許可協議約定的特定條件,雙方可另行協商許可協議的延長期限。Incyte擁有產品的全球開發和商業化權利,產品在美國及歐洲以Opzelura®的名稱銷售。Opzelura及其logo為Incyte的注冊商標。關於白癜風白癜風是一種慢性自身免疫性疾病,其特徵是皮膚色素脫失,其發病原因為產生色素的細胞即黑素細胞的缺失。據估算,中國白癜風患者約1,400萬[4]。白癜風患者中約85%為非節段型白癜風。外用皮質類固醇(TCS)及鈣調神經磷酸酶抑制劑(CI)均為非節段型白癜風的標籤外用藥,然而,這些現有外用藥物療法有長期用藥的不良反應或療效有限的臨床痛點[5、6]。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化,把控產品全生命週期管理的開放式平台型企業,致力於提供有競爭力的產品和服務,滿足尚未滿足的醫療需求。康哲藥業專注於全球首創(FIC)及同類最優(BIC)的創新產品,並高效推進創新產品臨床研究開發和商業化進程,賦能科研成果向診療實踐的持續轉化,造福患者。康哲藥業聚焦專科領域,擁有被驗證的商業化能力,廣泛的渠道覆蓋和多疾病領域專家資源,核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展,以鞏固心腦血管/消化業務競爭力,並將皮膚醫美、眼科業務獨立運營,培育專科小領域的大龍頭,提升專科規模效率。同時業務版圖拓展至東南亞市場,著力成為全球藥企進軍東南亞市場的「橋頭堡」,助力康哲藥業高品質持續健康發展。參考文獻/資料:1、FDA批準信息可在FDA官網查詢,網址:https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older2、FDA批準信息可在incyte官網查詢,網址:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream3、EMA批準信息可在EMA官網查詢,網址:https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura4、Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-75、《白癜風診療共識(2021版)》6、Kubelis-Lopez DE, Zapata-Salazar NA, Said-Fernandez SL, Sanchez-Dominguez CN, Salinas-Santander MA, Martinez-Rodriguez HG, Vazquez-Martinez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣,非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息,請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請,不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制,但康哲藥業並無進行任何說明或保證、明述或暗示,或其他表述,對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述,該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證,存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測,康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More
China Medical System: First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area ACN Newswire

China Medical System: First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area

SHENZHEN, CHINA, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product’s new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the "Hong Kong and Macau Medicine and Equipment Connect" policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in the Mainland of Greater Bay Area.In addition, on 24 September, the NDA for vitiligo indication of ruxolitinib cream has been accepted by the National Medical Products Administration of China (NMPA). In accordance with the relevant regulations of the drug real-world data application pilot program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”), CMS has conducted a real-world study on ruxolitinib cream in China. The results have shown positive efficacy, which is consistent with the key outcomes of global pivotal clinical studies. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Meanwhile, through the safety monitoring data of the Pilot Zone, no new safety events have been identified. Adverse events mostly had severity levels of grade 1 or 2. No adverse event (AE) leading to discontinuation or withdrawal, and no serious adverse event (SAE) related to the study drug occurred.If the Product is successfully approved for marketing in Mainland China, it will be the first prescription drug approved by NMPA for repigmentation in vitiligo, bringing this novel treatment hopes for Chinese vitiligo patients.Furthermore, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Pilot Zone on August 18, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. As of 30 June 2024, more than 3,200 patients have been treated with ruxolitinib cream in Boao Super Hospital.CMS has always been patient-oriented and innovation-driven based on clinical needs, continuously striving to improve drug accessibility. Benefited from the "Hong Kong and Macau Medicine and Equipment Connect" policy, ruxolitinib cream was approved for use in the Greater Bay Area and completed its first batch of prescriptions, shortening the time difference for Chinese vitiligo patients to use innovative drug and benefiting more domestic patients. Looking forward to the future, the Group will continuously strive to meet the unmet needs of Chinese patients, continuously explore novel drugs with international quality, and efficiently promote products’ clinical development and commercialization, so as to bring more quality pharmaceutical products through differentiated innovation-breakthrough, to safeguard the health and life-quality of patients.About ruxolitinib creamRuxolitinib cream (Opzelura), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older. As of now, it is the first and only treatment for repigmentation approved for use in the United States[1]. Ruxolitinib cream (Opzelura) is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[2]. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].On 2 December 2022, the Group through a subsidiary of the Company, a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases. In accordance with the License Agreement, the Group through CMS Skinhealth received an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The License Agreement commenced on its effective date and has a royalty term of ten years from the date of the commercial sale of the Product in the Territory (the “Royalty Term”). Upon the expiration of the Royalty Term, the License Agreement may be renewed for a period of ten years thereafter (the “Initial Extended Royalty Term”) as per certain conditions defined in the License Agreement. Upon the expiration of the Initial Extended Royalty Term, the License Agreement may be extended for a period otherwise agreed by both sides as per certain conditions defined in the License Agreement.Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. Opzelura and the Opzelura logo are registered trademarks of Incyte.About vitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million vitiligo patients in China[4]. Non-segmental vitiligo patients account for approximately 85% of them. Topical corticosteroids (TCS) and calcineurin inhibitors (CI) are used off-label for non-segmental vitiligo, however, these therapies have clinical deficiencies with long-term adverse reactions of long-term treatment or limited efficacy[5,6].About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference:1. Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older2. Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream3. Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura4. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-75. Consensus on the diagnosis and treatment of vitiligo (2021 version)6. Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, Vázquez-Martínez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Participation in the Multilateral System Remains High as Performance Drops, New Index Finds ACN Newswire

Participation in the Multilateral System Remains High as Performance Drops, New Index Finds

Washington, D.C., Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - Today marks the launch of the second edition of the Multilateralism Index from the International Peace Institute (IPI) and the Institute for Economics & Peace (IEP). The Index reveals that states remain engaged in the global multilateral system even as it increasingly struggles to address the crises it faces.Multilateralism Index 2024 ReportAn image of the front cover of the Multilateralism Index 2024 ReportKey resultsThe performance of the multilateral system declined across all five domains examined.Peace and security showed the steepest deterioration in performance, with the number of armed conflicts rising from 39 in 2013 to 55 in 2022.Climate action and human rights also saw significant declines in performance, despite increased engagement from member states.Participation in multilateral institutions has increased in most domains, even as performance has declined, indicating a shift from cooperation to contestation.Inclusivity improved across all domains, with steady growth in NGO engagement and women's representation in UN bodies.The Multilateralism Index 2024 presents a complex picture of global cooperation over the past decade, examining five crucial domains: Peace and Security, Human Rights, Climate Action, Public Health, and Trade. It reveals a contradiction: while participation in the multilateral system has largely held steady or even increased, its effectiveness in addressing global challenges has declined.Dr. Adam Lupel, IPI Vice President & COO said: "Over the past decade, we've witnessed a paradox in multilateralism. While participation in international institutions has largely held steady or even increased, the performance of the multilateral system in addressing global challenges has declined. This suggests a shift from cooperation to contestation at a time of transformation and rising global crises."The peace and security domain experienced the most significant deterioration in performance. Active armed conflicts increased from 39 in 2013 to 55 in 2022, with a notable rise in internationalized conflicts. The UN Security Council has seen more frequent use of the veto power, constraining its ability to respond to crises. However, states have not broadly pulled back from the UN peace and security architecture, and commitments in some areas, such as multilateral peacebuilding, have increased.Climate action presents another contradiction. Despite near-universal participation in the Paris Agreement and growing climate commitments, these commitments continue to fall short of necessary targets. Projections show an 8.8% increase in emissions by 2030, in stark contrast to the 43% decrease required to meet the critical 1.5°C target.The human rights domain exhibits a counterintuitive pattern. While engagement with UN human rights mechanisms has increased, global human rights protections have steadily declined. Most strikingly, members of the UN Human Rights Council consistently scored lower on human rights measures than the global average, indicating that many states are engaging less to advance human rights than to shape the direction of the system.Multilateral action on public health was significantly shaped by the COVID-19 pandemic, which reversed years of progress, particularly in areas such as childhood immunization. It also put the shortcomings of the global public health system in stark relief, spurring negotiations on an international pandemic agreement aimed at strengthening preparedness and response capabilities for future health crises.Trade is the one area where both performance and participation decreased. The paralysis of global trade negotiations and breakdown in adherence to global trade rules signal a shift away from multilateral approaches. This trend, combined with growing geopolitical tensions, creates challenges for global economic cooperation.Steve Killelea, Founder & Executive Chairman of IEP, commented: "The Multilateralism Index 2024 reveals a challenging trend: while engagement in global institutions has increased, their effectiveness has declined across key areas. There is a need to revitalize our multilateral system to address today's complex challenges."Despite these challenges, the Index highlights positive developments, particularly in the area of inclusivity. NGO engagement with the UN system has grown, and women's representation has increased across many UN bodies. However, the Global South remains underrepresented in many areas, suggesting that geographic inclusivity remains a work in progress.As the world contends with interconnected crises, from conflict to climate change, the Multilateralism Index 2024 provides valuable insights into the current state of global cooperation. It underscores the need for thoughtful reform to ensure that multilateral institutions can effectively address the complex challenges of the 21st century.Contact InformationMike KoslowskiIEP Senior Communications Advisormkoslowski@economicsandpeace.org+61418410531Related FilesMultilateralism Index 2024 - Full Press Release (1)Multilateralism Index 2024 - Full Press Release (1)SOURCE: International Peace Institute Copyright 2024 ACN Newswire via SeaPRwire.com.
More